Profile data is unavailable for this security.
About the company
KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
- Revenue in JPY (TTM)94.04bn
- Net income in JPY13.95bn
- Incorporated1948
- Employees1.13k
- LocationKaken Pharmaceutical Co Ltd20F, Bunkyo Green Court Center Office2-28-8, HonkomagomeBUNKYO-KU 113-8650JapanJPN
- Phone+81 359775001
- Fax+81 359775131
- Websitehttps://www.kaken.co.jp/
More ▼
Mergers & acquisitions
| Acquired company | 4521:TYO since announced | Transaction value |
|---|---|---|
| Aadi Bioscience Inc-Fyarro & Infrastructure Assets | -12.27% | 100.00m |
Data delayed at least 15 minutes, as of Jul 11 2025 07:30 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Katakura Industries Co Ltd | 40.12bn | 3.92bn | 85.82bn | 941.00 | 20.22 | 0.9236 | 12.34 | 2.14 | 120.54 | 120.54 | 1,233.12 | 2,638.59 | 0.2885 | 2.32 | 4.76 | 42,634,430.00 | 2.97 | 2.60 | 3.66 | 3.57 | 37.01 | 37.98 | 10.29 | 9.44 | 2.55 | -- | 0.0947 | 23.42 | -1.37 | -2.19 | 15.73 | 15.27 | -7.22 | 33.03 |
| Kyorin Pharmaceutical Co Ltd | 130.09bn | 9.09bn | 89.08bn | 2.00k | 9.40 | 0.6264 | 6.51 | 0.6848 | 158.16 | 158.16 | 2,264.40 | 2,372.28 | 0.7008 | 1.18 | 2.78 | 65,108,610.00 | 4.89 | 3.34 | 6.25 | 4.16 | 45.77 | 45.89 | 6.98 | 5.11 | 2.01 | -- | 0.1727 | 57.34 | 8.83 | 3.41 | 70.73 | 8.12 | 14.36 | -7.06 |
| Mochida Pharmaceutical Co Ltd | 105.16bn | 5.69bn | 104.84bn | 1.51k | 17.97 | 0.7815 | 12.16 | 0.997 | 160.36 | 160.36 | 2,966.32 | 3,686.67 | 0.6595 | 1.62 | 3.16 | 69,734,090.00 | 3.57 | 4.50 | 4.24 | 5.44 | 51.15 | 52.49 | 5.41 | 6.87 | 3.47 | 40.43 | 0.0026 | 43.01 | 2.21 | 0.6516 | 25.03 | 4.34 | 1.98 | 0.00 |
| Zeria Pharmaceutical Co Ltd | 87.31bn | 9.94bn | 108.47bn | 1.75k | 9.06 | 1.01 | 6.19 | 1.24 | 225.42 | 225.42 | 1,980.76 | 2,031.33 | 0.5638 | 1.51 | 3.70 | 50,006,380.00 | 6.44 | 4.67 | 9.95 | 7.47 | 73.25 | 72.17 | 11.42 | 9.02 | 0.9752 | -- | 0.3209 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
| Towa Pharmaceutical Co Ltd | 259.59bn | 18.99bn | 156.09bn | 4.79k | 7.86 | 0.8691 | 3.99 | 0.6013 | 385.70 | 385.70 | 5,273.63 | 3,486.39 | 0.5759 | 1.57 | 3.69 | 54,217,630.00 | 4.21 | 3.89 | 5.18 | 5.07 | 36.49 | 37.81 | 7.31 | 6.61 | 1.58 | -- | 0.5737 | 21.52 | 13.89 | 18.65 | 17.39 | 5.53 | 46.23 | 9.73 |
| Kaken Pharmaceutical Co Ltd | 94.04bn | 13.95bn | 166.32bn | 1.13k | 10.12 | 0.9481 | 10.08 | 1.77 | 372.31 | 372.31 | 2,464.10 | 3,974.44 | 0.5195 | 1.96 | 4.23 | 83,512,430.00 | 7.70 | 5.99 | 8.92 | 6.87 | 62.25 | 56.17 | 14.83 | 12.91 | 3.04 | -- | 0.0246 | 59.58 | 30.52 | 1.05 | 73.77 | -6.36 | 14.81 | 0.00 |
| Torii Pharmaceutical Co Ltd | 61.66bn | 5.56bn | 182.02bn | 592.00 | 31.98 | 1.47 | 30.56 | 2.95 | 197.61 | 197.61 | 2,193.40 | 4,311.56 | 0.4573 | 2.46 | 2.25 | 104,152,000.00 | 4.12 | 3.01 | 4.59 | 3.36 | 44.39 | 47.87 | 9.01 | 7.91 | 5.15 | -- | 0.00 | 61.32 | 10.59 | 7.04 | 22.41 | -28.70 | -19.90 | 20.11 |
| Kissei Pharmaceutical Co Ltd | 88.33bn | 11.96bn | 187.33bn | 1.78k | 14.66 | 0.8243 | 11.29 | 2.12 | 274.64 | 274.64 | 2,024.90 | 4,882.69 | 0.3498 | 1.73 | 3.04 | 49,679,420.00 | 4.74 | 4.26 | 5.11 | 4.60 | 49.89 | 48.59 | 13.56 | 14.30 | 4.95 | -- | 0.0075 | 32.41 | 16.87 | 6.91 | 7.18 | 33.54 | 31.04 | 13.97 |
| Sawai Group Holdings Co Ltd | 189.02bn | 2.17bn | 212.82bn | 3.31k | 197.84 | 1.22 | 12.22 | 1.13 | 9.32 | 82.53 | 1,518.81 | 1,505.86 | 0.5132 | 1.26 | 3.56 | 57,106,950.00 | 0.590 | -0.2327 | 0.8126 | -0.3187 | 29.81 | 32.95 | 1.15 | -0.475 | 0.8847 | 4.56 | 0.3536 | 191.65 | 6.88 | 0.7009 | -87.38 | -35.38 | 8.65 | 4.11 |
| Nippon Shinyaku Co Ltd | 160.23bn | 32.56bn | 221.29bn | 2.24k | 6.52 | 0.8592 | 5.74 | 1.38 | 483.40 | 483.40 | 2,379.02 | 3,666.27 | 0.5858 | 1.25 | 3.63 | 71,436,470.00 | 11.90 | 10.89 | 13.60 | 12.74 | 68.10 | 63.93 | 20.32 | 17.67 | 3.54 | -- | 0.0109 | 30.58 | 8.08 | 6.56 | 25.94 | 14.06 | 80.48 | 7.59 |
Data as of Jul 11 2025. Currency figures normalised to Kaken Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
17.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Silchester International Investors LLPas of 26 Mar 2024 | 2.22m | 4.82% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 1.25m | 2.73% |
| Nomura Asset Management Co., Ltd.as of 03 Jul 2025 | 1.02m | 2.23% |
| Goldman Sachs Asset Management LPas of 30 Apr 2025 | 693.50k | 1.51% |
| Brandes Investment Partners LPas of 03 Jul 2025 | 482.20k | 1.05% |
| Daiwa Asset Management Co. Ltd.as of 30 May 2025 | 480.70k | 1.05% |
| Nikko Asset Management Co., Ltd.as of 04 Jul 2025 | 479.70k | 1.04% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 473.03k | 1.03% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 391.50k | 0.85% |
| Asset Management One Co., Ltd.as of 03 Jul 2025 | 344.40k | 0.75% |
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
